5FA.F NIPRO CORP.
- Market cap
- EUR 1.21B
- P/E
- 17.2x
- P/B
- 0.67x
- ROE
- 5.4%
- Dividend yield
- 2.15%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is 5FA.F undervalued?
Graham number5FA.F trades 28.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
NIPRO CORP. fundamental analysis
No fundamental analysis for NIPRO CORP. yet.
NIPRO CORP. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About NIPRO CORP.
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses worldwide. The company offers renal products; interventional products, such as cardiovascular products, endovascular products, and accessories; and hospital products, including hypodermic needles, syringes, IV sets and catheters, 3-way stopcocks, infusion sets, balloon infusers, etc. It also provides cardiopulmonary products comprising oxygenato…
Full company profileNIPRO CORP. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
NIPRO CORP. annual financial statements (JPY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 495B | 545B | 587B | 645B | 661B | 670B |
| Gross Profit | 149B | 163B | 171B | 191B | 208B | 216B |
| Operating Income | 23.9B | 17.7B | 22.3B | 26.6B | 37.6B | 30.8B |
| EBITDA | - | 70.0B | 84.6B | 92.6B | 103B | 39.7B |
| Net Income | 13.5B | 4.57B | 11.1B | 5.11B | 13.5B | 15.4B |
| EPS | 82 | 28 | 68 | 31 | 83 | 94 |
| Balance Sheet | ||||||
| Total Assets | 930B | 1.03T | 1.11T | 1.17T | 1.21T | 1.22T |
| Total Liabilities | 730B | 785B | 840B | 859B | 879B | 877B |
| Shareholders' Equity | 185B | 206B | 233B | 252B | 274B | 283B |
| Cash & Short-term Investments | 95.3B | 89.7B | 99.7B | 107B | 97.8B | 105B |
| Cash Flow | ||||||
| Operating Cash Flow | 68.2B | 10.4B | 72.9B | 68.5B | 54.7B | - |
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | 68.2B | 10.4B | 72.9B | 68.5B | 54.7B | - |
| Ratios | ||||||
| ROE | 7.3% | 2.2% | 4.8% | 2.0% | 4.9% | 5.4% |
| ROA | 1.4% | 0.4% | 1.0% | 0.4% | 1.1% | 1.3% |
| Net Profit Margin | 2.7% | 0.8% | 1.9% | 0.8% | 2.0% | 2.3% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
NIPRO CORP. dividends
- Dividend yield
- 2.15%
- Forward dividend
- 0.17 EUR
- Payout ratio
- 27.9%
- Ex-dividend date
- Mar 30, 2027
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | JPY 3.76B | 23 | 27.9% |
| 2025 | JPY 4.41B | 27 | 86.2% |
| 2024 | JPY 3.03B | 19 | 27.2% |
| 2023 | JPY 4.25B | 26 | 92.9% |
| 2022 | JPY 5.22B | 32 | 38.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns NIPRO CORP.
- Insiders 9.92%
- Institutions 32.13%
- Public & others 57.95%
- Shares outstanding 163M
- Free float 155M
NIPRO CORP. company profile
- Company name
- NIPRO CORP.
- Ticker
- 5FA.F
- ISIN
- JP3673600007
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 38,593
- Fiscal year end
- March
- Address
- 3-26, Senriokashinmachi, Settsu, Japan, 566-8510
- Phone
- 81 6 6310 6804
- Website
- nipro.co.jp
About NIPRO CORP.
Nipro Corporation, together with its subsidiaries, engages in the medical devices, pharmaceuticals, and pharma packaging businesses worldwide. The company offers renal products; interventional products, such as cardiovascular products, endovascular products, and accessories; and hospital products, including hypodermic needles, syringes, IV sets and catheters, 3-way stopcocks, infusion sets, balloon infusers, etc. It also provides cardiopulmonary products comprising oxygenators, cardioplegia heat exchangers, perfusion tubing sets, arterial filters, hemoconcentrators, and venous and arterial cannulae; and enzymes, as well as contract development and manufacturing services. In addition, the company offers pharmaceutical combination products consisting of dual chamber bags, pre-filled syringes, and half-type kits; and integrated services, such as development, manufacturing, inspection, and packaging. Further, it provides glass containers, rubber stoppers, glass tubes, and other supplies for medical use; supplies for other industries; and drug administration systems, as well as autologous bone-marrow mesenchymal stem cells, culture products, and cell preservation products. The company was founded in 1947 and is headquartered in Settsu, Japan.
NIPRO CORP. management
8- Mr. Tsuyoshi YamazakiPresident & Representative Director · born 1968
- Mr. Takehito Yogo CPASenior MD, CFO & Director · born 1968
- Mr. Akihiko YamabeManager of Accounting Department - Corporate Planning Division
- Mr. Kimihito MinouraMD, Head of Value Engineering & Group DX Planning Office and Director · born 1972
- Mr. Toyoshi YoshidaSenior Executive Officer · born 1963
- Mr. Yasushi OyamaMD, Head of Global Innovation & Vascular Business Division and Director · born 1962
- Atsushi YonedaDirector, Production Technology Center & Director · born 1967
- Naoki OkamotoSenior Executive Officer